Junsheng Wang

发表

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.

Qi Li, P. Keegan, Jianxing He, 2022, Cancer cell.

Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial

Xudong Zhang, Qiming Wang, Tianjiang Ma, 2021, Translational lung cancer research.

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.

G. Jiang, Q. Fan, Feng Zhao, 2022, The lancet. Gastroenterology & hepatology.

Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.

Yufeng Cheng, Y. Hong, S. Luo, 2021 .

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China

H. Liang, Xiaojia Wang, Yongsheng Wang, 2022, Frontiers in Oncology.

Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).

Y. Ba, S. Qin, Likun Liu, 2018 .

Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.

Y. Ba, S. Qin, Likun Liu, 2018 .

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Wei Li, F. Gao, Y. Ba, 2023, BMC Medicine.

Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?

Y. Ba, M. Tao, S. Qin, 2018 .

Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial

Huijuan Wang, Yinghua Ji, Junsheng Wang, 2024, Nature communications.